Altimmune Inc. [NASDAQ: ALT] surged by $1.59 during the normal trading session on Tuesday and reaching a high of $15.37 during the day while it closed the day at $13.82. The company report on November 25, 2020 that Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December.
Simple, single-dose nasal spray offers greater ease and comfort of administration; positioning AdCOVID as a differentiated vaccine candidate for adults and children.
AdCOVID is capable of stimulating an additional and specialized type of immunity – local nasal mucosal immunity – believed to be critical for preventingfurther transmission of the virus.
Altimmune Inc. stock has also gained 49.57% of its value over the past 7 days. However, ALT stock has declined by -8.42% in the 3 months of the year. Over the past six months meanwhile, it has gained 65.91% and gained 631.22% year-on date.
The market cap for ALT stock reached $438.37 million, with 33.06 million shares outstanding and 30.91 million shares in the current float. Compared to the average trading volume of 1.68M shares, ALT reached a trading volume of 8168583 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Altimmune Inc. [ALT]:
B. Riley Securities have made an estimate for Altimmune Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 12, 2020. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on September 25, 2020, representing the official price target for Altimmune Inc. stock.
The Average True Range (ATR) for Altimmune Inc. is set at 1.17, with the Price to Sales ratio for ALT stock in the period of the last 12 months amounting to 68.50. The Price to Book ratio for the last quarter was 2.29, with the Price to Cash per share for the same quarter was set at 6.52.
ALT stock trade performance evaluation
Altimmune Inc. [ALT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 49.57. With this latest performance, ALT shares gained by 20.70% in over the last four-week period, additionally plugging by 65.91% over the last 6 months – not to mention a rise of 612.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALT stock in for the last two-week period is set at 66.04, with the RSI for the last a single of trading hit 75.87, and the three-weeks RSI is set at 58.78 for Altimmune Inc. [ALT]. The present Moving Average for the last 50 days of trading for this stock 11.71, while it was recorded at 11.18 for the last single week of trading, and 11.02 for the last 200 days.
Altimmune Inc. [ALT]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Altimmune Inc. [ALT] shares currently have an operating margin of -293.63. Altimmune Inc.’s Net Margin is presently recorded at -353.71.
Return on Total Capital for ALT is now -35.43, given the latest momentum, and Return on Invested Capital for the company is -42.83. Return on Equity for this stock declined to -43.74, with Return on Assets sitting at -37.72. When it comes to the capital structure of this company, Altimmune Inc. [ALT] has a Total Debt to Total Equity ratio set at 3.83. Additionally, ALT Total Debt to Total Capital is recorded at 3.69, with Total Debt to Total Assets ending up at 3.23. Long-Term Debt to Equity for the company is recorded at 3.26, with the Long-Term Debt to Total Capital now at 3.14.
Reflecting on the efficiency of the workforce at the company, Altimmune Inc. [ALT] managed to generate an average of -$820,805 per employee. Receivables Turnover for the company is 1.90 with a Total Asset Turnover recorded at a value of 0.11.Altimmune Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 34.70 and a Current Ratio set at 34.70.
Earnings per share (EPS) analysis for Altimmune Inc. [ALT] stock
With the latest financial reports released by the company, Altimmune Inc. posted -0.25/share EPS, while the average EPS was predicted by analysts to be reported at -0.26/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 3.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALT.
Altimmune Inc. [ALT]: Insider Ownership positions
There are presently around $303 million, or 66.40% of ALT stock, in the hands of institutional investors. The top three institutional holders of ALT stocks are: VR ADVISER, LLC with ownership of 4,500,000, which is approximately 0% of the company’s market cap and around 1.40% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 2,206,955 shares of the stock with an approximate value of $30.5 million in ALT stocks shares; and AVORO CAPITAL ADVISORS LLC, currently with $27.64 million in ALT stock with ownership of nearly New of the company’s market capitalization.
Positions in Altimmune Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 48 institutional holders increased their position in Altimmune Inc. [NASDAQ:ALT] by around 10,903,930 shares. Additionally, 29 investors decreased positions by around 2,304,732 shares, while 9 investors held positions by with 8,727,298 shares. The mentioned changes placed institutional holdings at 21,935,960 shares, according to the latest SEC report filing. ALT stock had 29 new institutional investments in for a total of 8,816,332 shares, while 14 institutional investors sold positions of 1,264,404 shares during the same period.